Products - Head and neck cancers | Topic | NICE

Showing 5 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma [ID6477]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 April 2026
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 December 2026
Suspected cancer update
Status:
In development
Expected publication date:
TBC
Sentinel Node Biopsy approved for pathological staging of clinically T1-T2 N0 oral cancer
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC